These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 26476534)

  • 41. Id-1 promotes migration and invasion of non-small cell lung cancer cells through activating NF-κB signaling pathway.
    Li J; Li Y; Wang B; Ma Y; Chen P
    J Biomed Sci; 2017 Dec; 24(1):95. PubMed ID: 29233161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin.
    Mi J; Zhang X; Rabbani ZN; Liu Y; Reddy SK; Su Z; Salahuddin FK; Viles K; Giangrande PH; Dewhirst MW; Sullenger BA; Kontos CD; Clary BM
    Mol Ther; 2008 Jan; 16(1):66-73. PubMed ID: 17912235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
    Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
    Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
    Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
    Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1.
    Ma Z; Cai H; Zhang Y; Chang L; Cui Y
    Biochem Biophys Res Commun; 2017 Aug; 490(2):309-316. PubMed ID: 28619508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a human NF-kappaB-activating protein, TAB3.
    Jin G; Klika A; Callahan M; Faga B; Danzig J; Jiang Z; Li X; Stark GR; Harrington J; Sherf B
    Proc Natl Acad Sci U S A; 2004 Feb; 101(7):2028-33. PubMed ID: 14766965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
    Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
    Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
    Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
    Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma.
    Zhan ZY; Zhong LX; Feng M; Wang JF; Liu DB; Xiong JP
    Int J Clin Exp Pathol; 2015; 8(5):5080-8. PubMed ID: 26191202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
    Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
    J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells.
    Saitoh Y; Martínez Bruyn VJ; Uota S; Hasegawa A; Yamamoto N; Imoto I; Inazawa J; Yamaoka S
    Lung Cancer; 2010 Dec; 70(3):263-70. PubMed ID: 20338663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
    Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
    Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
    Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
    Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. URGCP promotes non-small cell lung cancer invasiveness by activating the NF-κB-MMP-9 pathway.
    Cai J; Li R; Xu X; Zhang L; Wu S; Yang T; Fang L; Wu J; Zhu X; Li M; Huang Y
    Oncotarget; 2015 Nov; 6(34):36489-504. PubMed ID: 26429875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
    Xia Y; He Z; Liu B; Wang P; Chen Y
    Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.
    Yao F; Zhou W; Zhong C; Fang W
    Tumour Biol; 2015 Sep; 36(10):7873-9. PubMed ID: 25946971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.
    Zhang Y; Yu JH; Lin XY; Miao Y; Han Y; Fan CF; Dong XJ; Dai SD; Wang EH
    Virchows Arch; 2011 Sep; 459(3):255-63. PubMed ID: 21818639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.
    Li Z; Qu L; Zhong H; Xu K; Qiu X; Wang E
    Oncol Rep; 2014 Apr; 31(4):1707-14. PubMed ID: 24573418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.